AbbVie to Buy Cerevel Therapeutics for $8.7 Billion

AbbVie and Cerevel Therapeutics announced that AbbVie will buy Cerevel Therapeutics and its neuroscience pipeline of schizophrenia, Parkinson’s disease, and mood disorder drugs that are in multiple clinical and preclinical stages for $8.7 billion.

Under the terms of the transaction, AbbVie will acquire all outstanding shares of Cerevel for $45.00 per share in cash. The transaction is expected to close in the middle of 2024.

The acquisition — the second for AbbVie in a week — complements AbbVie’s neuroscience portfolio. On Nov. 30, AbbVie and ImmunoGen announced an agreement under which AbbVie will acquire ImmunoGen, and its flagship cancer therapy Elahere (mirvetuximab soravtansine-gynx) an antibody-drug conjugate (ADC) approved for platinum-resistant ovarian cancer, accelerating AbbVie’s presence in the solid tumor space.

To read the whole story, click here to subscribe.

Related Topics